Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma

• Published in: Esophagus : official journal of the Japan Esophageal Society 2022-10, Vol.19 (4), p.617-625
• Main Authors: Ito, Masaaki, Hiwasa, Takaki, Yajima, Satoshi, Suzuki, Takashi, Oshima, Yoko, Nanami, Tatsuki, Sumazaki, Makoto, Shiratori, Fumiaki, Li, Shu-Yang, Iwadate, Yasuo, Sugimoto, Kazuo, Mori, Masahiro, Kuwabara, Satoshi, Takizawa, Hirotaka, Shimada, Hideaki
• Format: Article
• Language: English
• Subjects: Antibodies; Biomarkers; Esophageal cancer; Gastroenterology; Medical prognosis; Medicine; Medicine & Public Health; Original Article; Squamous cell carcinoma; Surgical Oncology; Thoracic Surgery
• ISSN: 1612-9059; 1612-9067
• DOI: 10.1007/s10388-022-00939-0

Background Cofilin (CFL1, actin-binding protein) and β-actin (ACTB) are key molecules in the polymerization and depolymerization of actin microfilaments. The levels of these antibodies were analyzed, and the clinicopathological significance in patients with esophageal carcinoma were evaluated. Methods The levels of anti-CFL1 and anti-ACTB antibodies were analyzed in serum samples of patients with esophageal carcinoma and of healthy donors. Eighty-seven cases underwent radical surgery and the clinicopathological characteristics and prognosis was examined. Results Serum anti-CFL1 antibody (s-CFL1-Ab) levels and anti-ACTB antibody (s-ACTB-Ab) levels were significantly higher in patients with esophageal carcinoma than in healthy donors. Following the receiver operating characteristic curve analysis between healthy donors and esophageal carcinoma, the sensitivity and specificity for serum anti-CFL1 antibody (s-CFL1-Ab) were 53.3% and 68.8%. The sensitivity and specificity for serum anti-ACTB antibody (s-ACTB-Ab) were 54.9% and 67.7%, respectively. Univariate and multivariate analysis showed that s-CFL1-Ab and s-ACTB-Ab levels were not associated with sex, age, tumor depth, lymph node metastasis, or anti-p53-antibody levels. s-ACTB-Ab levels but not s-CFL1-Ab levels significantly correlated with squamous cell carcinoma antigen. Neither s-CFL1-Ab nor s-ACTB-Ab levels alone were obviously related to overall survival. However, patients with low s-CFL1-Ab levels and high s-ACTB-Ab levels exhibited significantly more unfavorable prognoses than those with high s-CFL1-Ab and low s-ACTB-Ab levels. Conclusions Serum levels of anti-CFL1 and anti-ACTB antibodies were significantly higher in patients with esophageal carcinoma than in healthy donors. A combination of low anti-CFL1 and high anti-ACTB antibodies is a poor prognostic factor in esophageal carcinoma.